We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+9.51%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$28.5B
AUM Growth
+$2.42B
(+9.3%)
Cap. Flow
+$581M
Cap. Flow
% of AUM
2.04%
Top 10 Holdings %
Top 10 Hldgs %
19.66%
Holding
1,921
New
171
Increased
1,320
Reduced
356
Closed
71
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$111M |
| 2 |
VF Corp
VFC
|
+$73.4M |
| 3 |
Amazon
AMZN
|
+$71M |
| 4 |
Stanley Black & Decker
SWK
|
+$60.2M |
| 5 |
Tesla
TSLA
|
+$46.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Target
TGT
|
+$158M |
| 2 |
Apple
AAPL
|
+$130M |
| 3 |
Cardinal Health
CAH
|
+$43.7M |
| 4 |
Fortinet
FTNT
|
+$39.6M |
| 5 |
ExxonMobil
XOM
|
+$32.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.73% |
| 2 | Industrials | 12.07% |
| 3 | Consumer Staples | 11.64% |
| 4 | Healthcare | 11.12% |
| 5 | Financials | 10.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
Bionano Genomics
BNGO
$12.7M
| $56.2K | ﹤0.01% |
64
+10
| +19% | +$12.6K |
|
|
BHIL
1727
DELISTED
Benson Hill, Inc.
BHIL
| $56.2K | ﹤0.01% |
629
+90
| +17% | +$8.81K |
|
|
CTEV
1728
Claritev Corp
CTEV
$368M
| $55.9K | ﹤0.01% |
1,216
+175
| +17% | +$14K |
|
1729
TETRA Technologies
TTI
$1.23B
| $55.4K | ﹤0.01% |
16,018
+2,296
| +17% | +$8.93K |
|
1730
OraSure Technologies
OSUR
$273M
| $54.7K | ﹤0.01% |
+11,355
| New | +$52.1K |
|
|
HLTH
1731
DELISTED
Cue Health Inc. Common Stock
HLTH
| $54.6K | ﹤0.01% |
26,369
+14,366
| +120% | +$45.4K |
|
1732
Unisys
UIS
$227M
| $53.6K | ﹤0.01% |
+10,499
| New | +$65.9K |
|
1733
IonQ
IONQ
$12.3B
| $52.8K | ﹤0.01% |
15,310
+2,211
| +17% | +$10.7K |
|
|
SRNE
1734
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $52.6K | ﹤0.01% |
59,354
+17,443
| +42% | +$23.1K |
|
1735
Marathon Digital Holdings
MARA
$4.62B
| $51.5K | ﹤0.01% |
15,064
+2,832
| +23% | +$23.8K |
|
1736
Lexicon Pharmaceuticals
LXRX
$1.02B
| $50.3K | ﹤0.01% |
26,324
+1,699
| +7% | +$3.62K |
|
1737
Clear Channel Outdoor Holdings
CCO
$1.23B
| $49.8K | ﹤0.01% |
47,458
+6,801
| +17% | +$8.56K |
|
|
SLGC
1738
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $48.3K | ﹤0.01% |
19,257
+2,761
| +17% | +$7.71K |
|
1739
Arlo Technologies
ARLO
$1.4B
| $48.3K | ﹤0.01% |
13,752
+1,795
| +15% | +$7.38K |
|
1740
Gevo
GEVO
$396M
| $48.1K | ﹤0.01% |
25,328
+3,629
| +17% | +$7.66K |
|
1741
Douglas Elliman
DOUG
$155M
| $47.6K | ﹤0.01% |
12,277
+1,600
| +15% | +$6.38K |
|
|
DM
1742
DELISTED
Desktop Metal, Inc.
DM
| $46.9K | ﹤0.01% |
3,450
+535
| +18% | +$11.2K |
|
|
TDAY
1743
USA Today Co
TDAY
$1.23B
| $46.3K | ﹤0.01% |
22,789
+3,066
| +16% | +$5.89K |
|
1744
Clover Health Investments
CLOV
$2.28B
| $46.2K | ﹤0.01% |
49,708
+7,124
| +17% | +$9.51K |
|
|
NPKI
1745
NPK International
NPKI
$1.21B
| $46.1K | ﹤0.01% |
+11,099
| New | +$40.7K |
|
1746
Precigen
PGEN
$1.93B
| $45.9K | ﹤0.01% |
30,203
+1,566
| +5% | +$2.69K |
|
1747
Ocular Therapeutix
OCUL
$1.86B
| $45.8K | ﹤0.01% |
16,284
+1,298
| +9% | +$4.3K |
|
|
ROVR
1748
DELISTED
Rover Group, Inc. Class A Common Stock
ROVR
| $44.2K | ﹤0.01% |
12,042
+1,819
| +18% | +$7.8K |
|
1749
Ardelyx
ARDX
$1.24B
| $44.2K | ﹤0.01% |
+15,504
| New | +$26.2K |
|
|
GBIO
1750
DELISTED
Generation Bio
GBIO
| $43.6K | ﹤0.01% |
1,110
+85
| +8% | +$4.46K |
|
Similar funds
ProShare Advisors's Q4 2022 Portfolio in Review
As of Q4 2022, ProShare Advisors held 1,921 positions worth $28.5B, up 9.3% from $26.1B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
ProShare Advisors's Q4 2022 filing shows 171 new, 1,320 increased, 356 reduced and 71 closed positions. Its largest new stake was Rivian: 689,839 shares worth $12.7M. The largest sale was Target, an estimated $158M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Industrials and Consumer Staples.
- ProShare Advisors's largest Q4 2022 buy was Rivian: 689,839 shares worth $12.7M.
- ProShare Advisors added most to Microsoft in Q4 2022, an estimated $111M increase.
- ProShare Advisors's biggest Q4 2022 reduction was Apple, cutting an estimated $130M.
- ProShare Advisors fully exited Target in Q4 2022, selling an estimated $158M.
- ProShare Advisors's ten largest holdings make up 20% of its $28.5B portfolio in Q4 2022.
- ProShare Advisors opened 171 new positions and closed 71 in Q4 2022.
- ProShare Advisors's portfolio value rose 9.3% quarter-over-quarter to $28.5B.
Based on ProShare Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.